Kai Huebel, Paolo Strati, Laurie Sehn, Julie Wu, Philomena Colucci, Oscar Bortolami, Christian Scholz. "Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes of high-risk patients." Blood (2025). https://doi.org/10.1182/blood-2025-5367